Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Immune Complex Corporation (AKA: Bios Development~Synthetic Genetics Inc)
Profile last edited on: 2/9/2023      CAGE: -----      UEI: ----------

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
1982
First Award
1986
Latest Award
2001
Program Status
Inactive (Acquired)
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

3347 Industrial Court Suite A
San Diego, CA 92121
   (619) 459-7083
   N/A
   N/A
Location: Single
Congr. District: 52
County: San Diego

Public Profile

Immune Complex Corporation manufactures and markets custom synthetic oligonucleotides used in detecting the presence of specific DNA sequences. The firm developed a vaccine delivery system based upon the Hepatitis- B core protein.In September1997 BioQuest, Inc. (NASDAQ: HIVX) acquired Immune Complex Corporation in a stock and cash deal.

Extent of SBIR involvement

User Avatar
Phase I Awards
12
Phase II Awards
5
Conversion Rate
41.67%
Phase I Dollars
$1,322,739
Phase II Dollars
$5,760,588
Total Awarded
$7,083,327

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2001 2 NIH $956,254
Project Title: Malaria Vaccine
2000 2 NIH $3,219,436
Project Title: Development of Antibodies to Human Cytochromes P450
2000 1 NIH $100,000
Project Title: Bioreactor Synthesis Of Cytochrome P450 Metabolites
1999 1 NIH $98,219
Project Title: High Throughout Colormetric Genotyping
1998 1 NIH $100,000
Project Title: Therapeutic Treatment For Chronic Human Renal Rejection

Key People / Management

  Henry J Barnes

  Ashley J Birkett

  David Johnson

  Ed Lusby

Company News

There are no news available.